-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cluster headache belongs to idiopathic headache disease—trigeminal autonomic cephalalgias (TACs).
Paroxysmal cluster headache is a primary headache disease characterized by a sudden onset of severe pain on one side of the head.
Eli Lilly and Company today announced that, Emgality® (galcanezumab) may reduce the frequency of seizures in adult patients with episodic cluster headache in the entire cluster period , and these patients for routine prevention of poor therapy response or intolerance, or contraindicated.
Emgality® (galcanezumab) can reduce the frequency of paroxysmal cluster headache in adult patients during the entire cluster period Emgality® (galcanezumab) can reduce the frequency of episodes in adult patients with paroxysmal cluster headache during the entire cluster period.
Dr.
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here